Bristol-Myers Squibb Company (BMY)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	29,780,000	28,075,000	26,890,000	28,669,000	31,770,000	27,632,000	28,074,000	27,086,000	27,273,000	26,796,000	30,186,000	30,121,000	33,262,000	31,443,000	29,161,000	27,111,000	30,192,000	34,277,000	34,343,000	31,853,000
Total current liabilities	US$ in thousands	23,774,000	22,638,000	23,265,000	25,822,000	22,262,000	23,462,000	20,150,000	19,085,000	21,890,000	18,930,000	20,915,000	22,821,000	21,868,000	21,460,000	18,991,000	17,330,000	19,080,000	20,464,000	23,421,000	19,232,000
Current ratio		1.25	1.24	1.16	1.11	1.43	1.18	1.39	1.42	1.25	1.42	1.44	1.32	1.52	1.47	1.54	1.56	1.58	1.67	1.47	1.66

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $29,780,000K ÷ $23,774,000K
= 1.25

The current ratio of Bristol-Myers Squibb Company has experienced fluctuations over the past few years, ranging from a high of 1.67 in September 2020 to a low of 1.11 in March 2024. Generally, a current ratio above 1 indicates that the company has more current assets than current liabilities, which suggests good liquidity and ability to meet short-term obligations.

However, the downward trend in the current ratio from 2022 to 2024 might indicate potential difficulties in meeting short-term obligations with current assets. It is important to closely monitor this trend to assess the company's liquidity position and financial health. Further analysis, including examining the composition of current assets and liabilities, as well as industry benchmarks, would provide a more comprehensive understanding of Bristol-Myers Squibb Company's current ratio dynamics.